GlassScriptPhysician profile
Sridevi Yangala
NPI 1114174687
$2,615.98
in general payments reported to CMS, 2019-2025
29 companies · $885 in 2025
The $885 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.53 · 2020: $61.58 · 2021: $42.93 · 2022: $305 · 2023: $768 · 2024: $478 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,130.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $382.20 | 2022-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $284.58 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.26 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $245.66 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $181.59 | 2021-2025 | Vraylar, Qulipta |
| Lilly USA, LLC | $173.66 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $162.44 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.03 | 2022-2023 | Xifaxan |
| Glaxosmithkline, LLC. | $110.46 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $86.71 | 2023-2025 | Cologuard Collection Kit |
| Medtronic, INC. | $81.55 | 2023 | Corevalve Evolut R |
| Procept Biorobotics Corporation | $70.21 | 2025 | |
| Philips North America LLC | $55.30 | 2019-2020 | |
| Daiichi Sankyo INC. | $54.11 | 2022 | |
| Merck Sharp & Dohme LLC | $46.99 | 2023 | Steglatro, Verquvo, Steglujan |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $46.82 | 2024 | |
| Averitas Pharma INC. | $32.36 | 2024 | Qutenza |
| Supernus Pharmaceuticals, INC. | $29.51 | 2019 | |
| Dexcom, INC. | $23.65 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $22.84 | 2024 | |
| Dendreon Pharmaceuticals LLC | $20.91 | 2020 | |
| Abbott Laboratories | $19.35 | 2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $17.22 | 2019 | |
| Astellas Pharma US INC | $16.70 | 2023 | Veozah |
| Actelion Pharmaceuticals US, INC. | $14.90 | 2025 | Uptravi, Opsumit |
| Biohaven Pharmaceuticals, INC. | $14.65 | 2021 | |
| Ibsa Pharma INC. | $14.59 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.12 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $13.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sridevi Yangala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.